Total Payments
$1.7M
2024 Payments
$136,178
Companies
15
Transactions
637
Medicare Patients
468
Medicare Billing
$49,287
Payment Breakdown by Category
Research$1.7M (98.8%)
Food & Beverage$11,583 (0.7%)
Travel$5,956 (0.3%)
Other$2,818 (0.2%)
Education$28.54 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 98 | 98.8% |
| Food and Beverage | $11,583 | 514 | 0.7% |
| Travel and Lodging | $5,956 | 16 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,818 | 4 | 0.2% |
| Education | $28.54 | 5 | 0.0% |
Payments by Type
Research
$1.7M
98 transactions
General
$20,385
539 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly Export S.A. Puerto Rico Branch | $1.3M | 66 | $0 (2024) |
| Eli Lilly and Company | $325,607 | 57 | $0 (2024) |
| Merck Sharp & Dohme LLC | $85,469 | 104 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $3,421 | 62 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $2,349 | 119 | $0 (2024) |
| Novo Nordisk Inc | $1,622 | 75 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,574 | 70 | $0 (2024) |
| ABBVIE INC. | $1,120 | 8 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $726.18 | 34 | $0 (2023) |
| Abbott Laboratories | $413.02 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $136,178 | 48 | Eli Lilly Export S.A. Puerto Rico Branch ($132,709) |
| 2023 | $130,024 | 53 | Eli Lilly and Company ($128,817) |
| 2022 | $101,502 | 57 | Eli Lilly and Company ($100,371) |
| 2021 | $331,527 | 70 | Eli Lilly Export S.A. Puerto Rico Branch ($322,252) |
| 2020 | $331,032 | 85 | Eli Lilly Export S.A. Puerto Rico Branch ($292,881) |
| 2019 | $405,088 | 84 | Eli Lilly Export S.A. Puerto Rico Branch ($391,823) |
| 2018 | $136,029 | 127 | Eli Lilly Export S.A. Puerto Rico Branch ($80,821) |
| 2017 | $165,719 | 113 | Eli Lilly Export S.A. Puerto Rico Branch ($93,467) |
All Payment Transactions
637 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Diabetes Care | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: DIABETES | ||||||
| 11/26/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $31.44 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: DIABETES | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/14/2024 | Eli Lilly Export S.A. Puerto Rico Branch | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Obesity | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: Diabetes | ||||||
| 10/03/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: IMMUNOLOGY | ||||||
| 10/01/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Diabetes Care | ||||||
| 09/27/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $68,009.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/23/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $64,560.00 | Research |
| Study: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | ||||||
| 09/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: DIABETES | ||||||
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/28/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Diabetes | ||||||
| 08/27/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: Endocrinology | ||||||
| 08/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: DIABETES | ||||||
| 07/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: DIABETES | ||||||
| 07/15/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/03/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: Diabetes Care | ||||||
| 06/26/2024 | Eli Lilly Export S.A. Puerto Rico Branch | TRULICITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Diabetes | ||||||
| 06/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: DIABETES | ||||||
| 06/12/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/05/2024 | Eli Lilly Export S.A. Puerto Rico Branch | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Diabetes | ||||||
| 06/04/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly Export S.A. Puerto Rico Branch | $320,514 | 2 |
| A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN STUDY PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS PREVIOUSLY TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly Export S.A. Puerto Rico Branch | $268,438 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly Export S.A. Puerto Rico Branch | $230,018 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly Export S.A. Puerto Rico Branch | $191,310 | 3 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly Export S.A. Puerto Rico Branch | $161,021 | 3 |
| A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared with the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine in Subjects with Type 2 Diabetes Mellitus | Merck Sharp & Dohme Corporation | $84,570 | 61 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $81,930 | 2 |
| A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $71,997 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly Export S.A. Puerto Rico Branch | $68,009 | 1 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly Export S.A. Puerto Rico Branch | $64,560 | 1 |
| A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $53,677 | 1 |
| A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN STUDY PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS PREVIOUSLY TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $28,265 | 2 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $23,794 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $16,171 | 2 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $15,064 | 2 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $12,800 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $9,829 | 2 |
| SAFETY AND EFFICACY OF HUMAN REGULAR U-500 INSULIN ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTIONS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS - A RANDOMIZED, OPEN-LABEL, PARALLEL CLINICAL TRIAL | Eli Lilly Export S.A. Puerto Rico Branch | $9,504 | 1 |
| A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $1,952 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $1,945 | 2 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $979.32 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $297.96 | 1 |
| SAFETY AND EFFICACY OF HUMAN REGULAR U-500 INSULIN ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTIONS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS - A RANDOMIZED, OPEN-LABEL, PARALLEL CLINICAL TRIAL | Eli Lilly and Company | $38.10 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND COMPARISON OF LY900014 AND FIASP, BOTH IN COMBINATION WITH BASAL INSULIN IN ADULTS WITH TYPE 1 DIABETES PROTO COMPARE | Eli Lilly and Company | $30.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 88 | 139 | $11,268 | $7,271 |
| 2022 | 3 | 98 | 192 | $16,809 | $9,582 |
| 2021 | 4 | 168 | 292 | $30,232 | $20,029 |
| 2020 | 3 | 114 | 195 | $18,371 | $12,406 |
Total Patients
468
Total Services
818
Medicare Billing
$49,287
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 44 | 94 | $6,486 | $4,004 | 61.7% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 25 | 25 | $2,830 | $1,890 | 66.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 20 | $1,952 | $1,377 | 70.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 135 | $11,507 | $6,517 | 56.6% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 30 | 39 | $4,353 | $2,757 | 63.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 13 | 18 | $948.72 | $307.31 | 32.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 56 | 139 | $12,799 | $7,258 | 56.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 46 | 66 | $8,686 | $6,451 | 74.3% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 44 | 60 | $7,205 | $5,650 | 78.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 22 | 27 | $1,542 | $668.84 | 43.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 50 | 105 | $8,073 | $4,844 | 60.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 52 | $5,783 | $4,101 | 70.9% |
| 76536 | Ultrasound of head and neck | Office | 2020 | 29 | 38 | $4,515 | $3,461 | 76.7% |
About Dr. Martha Gomez, MD
Dr. Martha Gomez, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in San Juan, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003822651.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martha Gomez, MD has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $136,178 received in 2024. These payments were reported across 637 transactions from 15 companies. The most common payment nature is "" ($1.7M).
As a Medicare-enrolled provider, Gomez has provided services to 468 Medicare beneficiaries, totaling 818 services with total Medicare billing of $49,287. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location San Juan, PR
- Active Since 08/01/2006
- Last Updated 02/03/2025
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1003822651
Products in Payments
- JANUVIA (Drug) $85,236
- HUMULIN (Drug) $9,542
- TOUJEO (Drug) $1,494
- FARXIGA (Drug) $1,483
- JARDIANCE (Drug) $1,321
- Synthroid (Drug) $1,036
- SOLIQUA 100/33 (Biological) $669.74
- Ozempic (Drug) $655.90
- INVOKANA (Drug) $575.25
- TRADJENTA (Drug) $493.30
- SOLIQUA (Drug) $472.47
- LOKELMA (Drug) $387.55
- BYDUREON (Drug) $340.56
- Victoza (Drug) $336.54
- TRULICITY (Drug) $335.86
- SOTAGLIFLOZIN (Drug) $300.00
- Rybelsus (Drug) $264.14
- Minimed 670G System (Device) $230.08
- FreeStyle Libre (Device) $203.33
- LANTUS (Drug) $181.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in San Juan
Dr. Manuel Alegre-Hernandez, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $365,694
Endocrinology, Diabetes & Metabolism $365,694
Meliza Martinez Rodriguez, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $173,612
Endocrinology, Diabetes & Metabolism $173,612
Dr. Jorge De Jesus Miranda, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $69,518
Endocrinology, Diabetes & Metabolism $69,518
Oscar Ruiz-Bermudez, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $44,199
Endocrinology, Diabetes & Metabolism $44,199
Dr. Gildred Colon, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $39,809
Endocrinology, Diabetes & Metabolism $39,809
Dr. Harry Jimenez, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $32,445
Endocrinology, Diabetes & Metabolism $32,445